
Loyal Secures $100M Series C Funding to Advance Development of First Canine Longevity Drug
Loyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity Drug Loyal, a clinical-stage animal health company developing lifespan extension drugs for dogs, announced today that it has raised $100M in Series C funding. age1, the…












